Chitin or derivatives thereof for the prevention and/or treatment of parasitoses

US9717751B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9717751-B2
Application numberUS-201314648919-A
CountryUS
Kind codeB2
Filing dateDec 10, 2013
Priority dateDec 14, 2012
Publication dateAug 1, 2017
Grant dateAug 1, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The subject matter of the present invention is the use of chitin or a derivative of chitin for preventing and/or treating parasitoses, and in particular cryptosporidiosis. The present invention also pertains to a composition that comprises at least one base agent chosen from among chitin or a derivative of chitin and at least one secondary agent chosen from among an agent for stimulating immunity and an antiparasite agent, as well as the use of same for preventing and/or treating parasitoses, in particular cryptosporidiosis.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method for treating cryptosporidiosis comprising administering to humans or animals infected with Cryptosporidium a composition comprising a base agent and an agent for stimulating immunity, wherein the base agent is chosen from chitin or a chitin derivative comprising chitosan, N-acetylglucosamine or glucosamine, and the agent for stimulating immunity is chosen from a yeast cell wall, a yeast extract, selenium, a bacterium of the Bacillus, Lactobacillus, Bifidobacterium, Enterococcus, Propionibacterium, Pediococcus or Lactococcus genus, a yeast of the Saccharomyces or Kluyveromyces genus, or a combination thereof. 2. The method as claimed in claim 1 , wherein the composition also comprises an antiparasitic agent chosen from an essential oil, active carbon, lauric acid, or combinations thereof. 3. The method as claimed in claim 2 , wherein the essential oil is chosen from garlic essential oil, citronella essential oil, cinnamon essential oil, thyme essential oil, oregano essential oil, tea tree essential oil, lemon essential oil, eucalyptus essential oil, or combinations thereof. 4. The method as claimed in claim 1 , wherein the selenium is in the form of a selenium-enriched yeast, selenium totally or partially extracted from yeast, or combinations thereof. 5. The method as claimed in claim 1 , wherein the composition is a food composition, a food supplement or a pharmaceutical composition.

Assignees

Inventors

Classifications

  • Antiparasitic agents · CPC title

  • Sulfur, selenium or tellurium; Compounds thereof · CPC title

  • Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender · CPC title

  • Lactobacilli, e.g. L. acidophilus or L. brevis · CPC title

  • A61K31/722Primary

    Chitin, chitosan · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9717751B2 cover?
The subject matter of the present invention is the use of chitin or a derivative of chitin for preventing and/or treating parasitoses, and in particular cryptosporidiosis. The present invention also pertains to a composition that comprises at least one base agent chosen from among chitin or a derivative of chitin and at least one secondary agent chosen from among an agent for stimulating immuni…
Who is the assignee on this patent?
Lesaffre & Cie
What technology area does this patent fall under?
Primary CPC classification A61K31/722. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Aug 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).